ArticleBrain imaging and behavior2026
Magnetic resonance spectroscopy study of cognitive impairment associated with cerebral small vessel disease.
Article in Brain imaging and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to examine the association between cognitive decline and brain substance metabolism, as well as the risk factors in cerebral small vessel disease(CSVD) patients.
methodsThe CSVD patients were divided into a simple CSVD group and a CSVD-related cognitive impairment group according to the Montreal Cognitive Assessment (MoCA) score. Healthy patients were selected as the normal control group. Magnetic Resonance Imaging (MRI) was used to scan the frontal lobe, hippocampus, and semioval center of the dominant hemisphere of all subjects. The N-acetylaspartic acid (NAA), creatine (Cr), and choline (Cho) were measured.
resultsThere were statistically significant differences in visual space, executive function, naming, and abstract thinking between simple CSVD group and CSVD-related cognitive dysfunction group. A history of hypertension, triglycerides, low-density lipoprotein and Homocysteine (Hcy) levels were risk factors for CSVD-related cognitive impairment. The frontal lobe NAA/Cr ratio decreased in the simple CSVD group, the frontal lobe NAA/Cho ratio decreased in the CSVD-related cognitive impairment group, and the semiovale center NAA/Cr ratio decreased. NAA/Cho in the dominant hemisphere of the hippocampus was positively correlated with MoCA scores, frontal NAA/Cr was positively correlated with MoCA scores, and NAA/Cr in the center of the semioval was negatively correlated with MoCA scores.
conclusionsHypertension, abnormal blood lipid metabolism and high levels of Hcy are risk factors for CSVD-related cognitive dysfunction. The patients with CSVD-related cognitive dysfunction have visual space and executive function deficiency. Poor abstract thinking may be related to metabolic abnormalities in the frontal lobe and hippocampus.NAA/Cho and NAA/Cr can be used as sensitive indicators of cognitive dysfunction.
Indexed as
Identifiers
41760793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.